Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

TFF Pharma Inks Research Pact With US Army For Dry Powder Medical Countermeasures

TFF Pharmaceuticals Inc (NASDAQ:TFFP) has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for defensive research into countermeasures against biological warfare.

  • Under the terms of the CRADA, TFF Pharma and USAMRIID will evaluate the immune response of a dry powder recombinant Vesicular Stomatitis Virus Severe Acute Respiratory Syndrome Coronavirus-2 Glycoprotein (TFFD-rVSV-SARS2-GP) vaccine formulated using TFF's Thin Film Freezing technology. 
  • USAMRIID will assess the immunogenicity and protective efficacy of inhaled dry powder formulation against SARS-CoV-2 induced in an animal model compared to the intramuscular administration.
  • Related: TFF Pharma's Inhaled Niclosamide Shows Potent Activity Against Omicron Variant.
  • Earlier in 2021, under the existing CRADA, TFF Pharmaceuticals announced positive preclinical data showing the two Thin Film Freezing-formulated biodefense countermeasures maintained efficacy in an in vitro viral neutralization assay. 
  • TFF Pharmaceuticals' Thin Film Freezing (TFF) platform is designed to improve the solubility and absorption of poorly water-soluble drugs. It is particularly suited to generate dry powder particles with properties targeted for inhalation delivery.
  • Price Action: TFFP shares are up 9.32% at $6.57 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.